EAA Publications:

Julian E., Belleman T., Garcia MJ., Rutten-van Mölken M., Doeswijk R., Giuliani R., Wörmann BJ., Widmer D., Tilleul P., Casado Arroyo R., Strammiello V., Morgan K., Guardian M., Ermisch M., Bernardini R., Gianfrate F., Capri S., Uyl-de Groot CA., Pavlovic M., Ruof J.: EU HTA: Avoiding Error and Finding the Right Balance: Insights generated by the European Access Academy. JMAHP 13(1), 6. (2025). doi: https://doi.org/10.3390/jmahp13010006

Gsteiger S., Bucher HC., Ryan J., Ruof J.: Technology Assessment vs. Technology Appraisal - How to Strengthen the Science/Value Dichotomy with EU HTA?. JMAHP 12(4), 369-377 (2024). doi: https://doi.org/10.3390/jmahp12040028

Julian E., Solà-Morales O., Garcia MJ., Brinkhuis F., Pavlovic M., Martín Saborido C., Doeswijk R., Giuliani R., Willemsen A., Goettsch W., Wörmann BJ., Dafni U., Bucher HC., Valderrama BP., Bernardini R., Gianfrate F., Uyl.de Groot CA., Ruof J.: The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights generated at the 2023 Fall Convention and Survey of the European Access Academy. JMAHP 12(3), 128-143, (2024). doi: https://doi.org/10.3390/jmahp12030011

Brinkhuis F., Julian E., van den Ham H., Gianfrate F., Strammiello V., Berntgen M., Pavlovic M., Mol P., Wasem J., van Dyck W., Cardone A.,

Dierks C., Schiel A., Bernardini R., Solà-Morales O., Ruof J., Goettsch W.: Navigating the path towards successful implementation of the EU HTA Regulation: Key takeaways from the 2023 Spring Convention of the European Access Academy. Health Res Policy Sys 22,74 (2024). doi: https://doi.org/10.1186/s12961-024-01154-2

Brinkhuis F., Ruof J., van den Ham H., Gianfrate F., Strammiello V., Berntgen M., Pavlovic M., Mol P., Wasem J., van Dyck W., Cardone A.,

Dierks C., Schiel A., Solà-Morales O., Goettsch W., Julian E.: Evaluating progress towards implementation of the European HTA Regulation: Insights generated from the European Access Academy's multi-stakeholder survey. Health Policy and Technology 13(5), 100930, (2024). doi: https://doi.org/10.1016/j.hlpt.2024.100930

Desmet T., Julian, E., Van Dyck W., Simoens S., Huys I., Giuliani R., Toumi M., Dierks C., Dierks J., Cardone A., Houÿez F., Pavlovic M., Berntgen M., Mol P., Schiel A., Goettsch W., Gianfrate F., Capri S., Ryan J., Ducournau P., Solà-Morales O., Ruof J.: An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators. JMAHP 12(1), 21-34, (2024). doi: https://doi.org/10.3390/jmahp12010004

Van Haesendonck L., Ruof J., Desmet T., Van Dyck W., Simoens S., Huys I., Giuliani R., Toumi M., Dierks C., Dierks J., Cardone A., Houÿez F., Pavlovic M., Berntgen M., Mol P., Schiel A., Goettsch W., Gianfrate F., Capri S., Ryan J., Ducournau P., Solà-Morales O., Julian E.: The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire. JMAHP 11,  1, (2023). doi: https://doi.org/10.1080/20016689.2023.2217543

Julian E., Gianfrate F., Sola-Morales O., Mol PGM., Bergmann JF., Salmonson T., Hebborn A., Grande M., Ruof J.: How can a Joint European Health Technology Assessment provide an 'Additional Benefit' over the current Standard of National Assessments?. Health Econ. Rev. 12, 30 (2022). doi: https://doi.org/10.1186/s13561-022-00379-7

Julian E., Pavlovic M., Solá-Morales O., Gianfrate F., Toumi M., Bucher H.C., Dierks C., Greiner W., Mol P., Bergmann JF., Salmonson T., Hebborn A., Grande M., Cardone A., Ruof J.: Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy. Health Econ. Rev. 12, 54 (2022). doi: https://doi.org/10.1186/s13561-022-00402-x

Journal of Market Access & Health Policy - Special Issue on EU HTA:

The European Access Academy (EAA) and the Market Access Society (MAS) joined forces to edit a Special Issue of the Journal of Market Access and Health Policy focused on the EU-HTA.

The full issue can be accessed online HERE

Manuscripts published in the Special Issue (as editorials, research papers, other) to date:

Casali PG., Capri S.: A New Health Networking Infrastructure on Cancer Is Taking Shape in Europe: A Not-to-Miss Opportunity for the EU Regulatory System. JMAHP 13(2), 18 (2025). doi: https://doi.org/10.3390/jmahp13020018

Nisticò R.: Agenzia Italiana del Farmaco (AIFA): Developments and Strategy in a Transitioning European HTA Landscape. JMAHP 13(1), 5 (2025). doi: https://doi.org/10.3390/jmahp13010005

Morgese P., Majors S., Patel D.: ARM’s Perspective on the First Joint Clinical Assessments for ATMPs: Challenges and Opportunities on the Path Ahead. JMAHP 13(2), 14 (2025). doi: https://doi.org/10.3390/jmahp13020014 

Wang T., McAuslane N.: Ensuring the Efficiency and Effectiveness of Joint Clinical Assessment in National HTA Decision-Making: Insights from the 2024 CIRS Multi-Stakeholder Workshop. JMAHP 13(1), 9 (2025). doi: https://doi.org/10.3390/jmahp13010009

Julian E., Belleman T., Garcia MJ., Rutten-van Mölken M., Doeswijk R., Giuliani R., Wörmann BJ., Widmer D., Tilleul P., Casado Arroyo R., Strammiello V., Morgan K., Guardian M., Ermisch M., Bernardini R., Gianfrate F., Capri S., Uyl-de Groot CA., Pavlovic M., Ruof J.: EU HTA: Avoiding Error and Finding the Right Balance: Insights generated by the European Access Academy. JMAHP 13(1), 6. (2025). doi: https://doi.org/10.3390/jmahp13010006

Broich K., Löbker W.: Towards a Unified European View of Clinical Evidence: What ‘Health Technology Assessment Organizations’ Can Learn from Regulatory Experience. JMAHP 13(2), 19 (2025). doi: https://doi.org/10.3390/jmahp13020019

Beekman J., de Roo A., Wolters S., Marapin R., Gurgel do Amaral G., Dvortsin E., Quilici S., de Waure C., Petelos E., Postma M., Viceré A.: Strengthening the EU Health Technology Assessment Regulation: Integrating National Immunization Technical Advisory Groups for Comprehensive Vaccine Assessments. JMAHP 13(1), 16 (2025). doi: https://doi.org/10.3390/jmahp13020016

Merész G., Dankó D., Molnár MP.:Public Health Decision-Maker Perspective on Joint Clinical Assessments in Central European EU Member States. JMAHP 13(1), 10 (2025). doi: https://doi.org/10.3390/jmahp13010010

Tanner S., Coady R., Lisica A., Falla E., van Engen A.: The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?JMAHP 13(1), 3 (2025). doi: https://doi.org/10.3390/jmahp13010003

Gsteiger S., Bucher HC., Ryan J., Ruof J.: Technology Assessment vs. Technology Appraisal—How to Strengthen the Science/Value Dichotomy with EU HTA? JMAHP 12(4), 369-377 (2024). doi: https://doi.org/10.3390/jmahp12040028 - 18

Andrew Wilson

(Co-Director, Leeder Centre for Health Policy, Economics and Data, University of

Sydney, Chair, Australian HTA Review Implementation Advisory Group)

Abstract

Presentation
Recording:

Christian Dierks

(Professor for Health Services Research, Charité Berlin, CEO at Dierks+ Company)

Abstract

Presentation
Recording:

EAA Fall Convention October 2023

Haemato- / Oncology - A Pace Maker for EU HTA

Download the Proceedings of the EAA Fall Convention 2023 HERE.

Visit our YouTube channel for all EAA video recordings.

Brian Cuffel

(VP & Head of Market Access Oncology at Bayer Pharmaceuticals)



Presentation

Abstract

Abstract

Andrew Wilson

(Chair, Pharmaceutical Benefits Advisory Committee, Australian Department of Health and Aged Care &  Co-Director, Menzies Centre for Health Policy and Economics, University of Sydney)

Abstract

Abstract

Abstract

Ansgar Hebborn

(Head, European Access Policy Affairs, Roche & Chair of the HTA Working Group, EFPIA)



Abstract